RegisterLogin

Crizotinib-d5

CAT: 0804-HY-50878SSize: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-50878SSize:1 mg
Selected
PRICE
AVAILABILITY
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Crizotinib-d5 is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition[1][2][3].
CAS Number
[1395950-84-1]
Product Name Alternative
PF-02341066-d5
UNSPSC
12352005
Hazard Statement
H302+H312+H332, H315, H319
Target
Anaplastic lymphoma kinase (ALK) ; Autophagy; c-Met/HGFR; ROS Kinase
Type
Isotope-Labeled Compounds
Related Pathways
Autophagy; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Purity
99.7
Solubility
DMSO : 20mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 0.1mg/mL (ultrasonic)
Smiles
NC1=C(C=C(C=N1)C2=CN(N=C2)C3(C([2H])(CNCC3([2H])[2H])[2H])[2H])O[C@H](C)C4=C(C=CC(F)=C4Cl)Cl
Molecular Formula
C21H17D5Cl2FN5O
Molecular Weight
455.37
Precautions
H302+H312+H332, H315, H319
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Shen A, et al. c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers. Cancer Res. 2015 Nov 1;75 (21) :4548-59.|[3]Umapathy G, et al. The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma. Sci Signal. 2014 Oct 28;7 (349) :ra102.|[4]Tucker ER, et al. Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma. Mol Oncol. 2017 Aug;11 (8) :996-1006.|[5]Liu H, et al. Identifying and Targeting Sporadic Oncogenic GeneticLiu H, et al. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer. Cancer Discov. 2018 Mar;8 (3) :354-369.|[6]Cui JJ, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) . J Med Chem. 2011 Sep 22;54 (18) :6342-63.|[7]Cullinane C, et al. Differential (18) F-FDG and 3'-deoxy-3'- (18) F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models. J Nucl Med. 2011 Aug;52 (8) :1261-7|[8]Christensen JG, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007, 6 (12 Pt 1), 3314-3322.|[9]Zou HY, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007, 67 (9), 4408-4417.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Related Products

CatalogName
HY-50878-01Crizotinib
HY-149696IR-Crizotinib
HY-50878S1Crizotinib-d8
HY-50878S2Crizotinib-d9
HY-100549-01(S) -Crizotinib
HY-50878A-01Crizotinib (hydrochloride)
HY-50878R-01Crizotinib (Standard)
HY-50878BCrizotinib (acetate)
HY-50878ASCrizotinib-d9 (hydrochloride)
HY-13320-012-Keto Crizotinib

Alternative Products

CatalogName
RM-C182642-01Crizotinib-D5
TMIJ-0115-01Crizotinib-d5
TRC-C785001-5MG(R)-Crizotinib-d5 (piperidine-3,3,4,5,5-d5)
TRC-C785001-10MG(R)-Crizotinib-d5 (piperidine-3,3,4,5,5-d5)
T1661-01Crizotinib
M16370-01Crizotinib
4368/10Crizotinib
202222Crizotinib
C07488-01Crizotinib
ENZ-CHM183-0005Crizotinib

Popular Products